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INTRODUCTION 
Factor XII (FXII) is a plasma glycoprotein and clotting 
factor that participates in coagulation and fi brinolysis, 
and has a role in infl ammatory processes. FXII starts 
the coagulation cascade and infl ammatory processes 
via the intrinsic coagulation pathway and the bradyki-
nin-producing kallikrein-kinin system (1).
Activation of FXII leads to thrombin generation due 
to a series of proteolytic reactions and plays a role in 
thrombus formation (2).
FXII defi ciency is a rare blood disorder that causes 
prolonged coagulation test-activated partial thrombo-
plastin time (aPTT) mimicking bleeding diathesis but 
without the presence of clinically signifi cant bleeding 
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a history of severe obesity and arterial hypertension, which in 2010 developed deep vein thrombosis (DVT) of the right arm 
during hormone replacement therapy. Laboratory findings showed prolonged aPTT. Warfarin was introduced into therapy 
for two years, followed by treatment with acetylsalicylic acid, without hemorrhagic complications. In January 2014, after 
cholecystectomy she developed pulmonary embolism, DVT of the right leg, with very prolonged aPTT verified again (>150 
s), clinically without signs of hemorrhagic diathesis. She was treated with low molecular weight heparin with bridging to 
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Repeating prolonged aPTT in a person with no signs of bleeding diathesis requires diagnostic workup for the possible 
lack of contact factors including FXII. The presented patient with acquired and hereditary thrombophilia and recurrent 
thrombotic incidents has an indication for long term dual anticoagulant and antiaggregation therapy that is well tolerated 
without bleeding complications.
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tendencies. It was fi rst described in 1955. Factor XII 
is also known as Hageman factor, named aft er the pa-
tient in whom this condition was fi rst diagnosed and 
who later died due to massive pulmonary embolism 
aft er immobility (2-4).
Inherited FXII defi ciency is in general an autosomal 
recessive disorder but FXII defi ciency may also be an 
acquired disorder (4). Th e incidence of FXII defi cien-
cy is approximately 1/1 000 000 individuals (4,5), and 
the prevalence of moderate and severe FXII defi ciency 
is 1.5%-3% in the general population (6). Factor XII 
levels are lower in patients of Asian descent (7).
On the other hand, acquired FXII defi ciency has been 
occasionally described in patients with leukemia, ne-
phrotic or antiphospholipid syndrome (8,9).
Chronic myeloproliferative neoplasms (MPNs) in-
clude chronic myeloid leukemia, chronic neutrophil-
ic leukemia, polycythemia vera (PV), primary my-
elofi brosis (PMF), essential thrombocythemia (ET), 
chronic eosinophilic leukemia not otherwise specifi ed 
and MPN unclassifi able (MPN-U) (10). Th ey are as-
sociated with an acquired thrombophilic state due to 
abnormalities of MPN-clone derived blood cells and 
normal vascular cells, which acquire a prothrombotic 
phenotype and release circulating procoagulant mi-
croparticles, as well as acquired activated protein C 
resistance (11).
JAK2 mutation has been identifi ed in most patients 
with PV and in about half of patients with PMF and 
ET, and has been associated with a higher incidence of 
thrombosis (12-14).
MPNs accompanied with coagulation factor defi cien-
cy have rarely been described in the literature. Ac-
quired hemophilia and acquired von Willebrand syn-
drome with bleeding diathesis in patients with MPN, 
especially ET, has been reported a few times (15-17), 
while ET with FXII defi ciency has been described in 
just one case report where the patient presented with 
severe hemorrhage (9).
In this work, we present the fi rst case report, accord-
ing to our knowledge, of a patient with JAK2-muta-
tion positive MPN accompanied with severe factor 
XII defi ciency and recurrent thromboembolic events, 
without any hemorrhagic diathesis. In addition, we 
performed a review of the literature using PubMED 
database regarding FXII defi ciency, its clinical signif-
icance and open questions associated with that rare 
coagulation disorder.
CASE REPORT 
A Caucasian female born in 1959 was referred in De-
cember 2014 to a hematologist at the Center for Inheri-
ted and Acquired Disorders of Hemostasis, Zagreb 
University Hospital Center in Zagreb, Croatia, due 
to prolonged aPTT (>150 s). She had a history of ex-
treme obesity, arterial hypertension and an abortion in 
the fi rst trimester. Her family history was positive for 
vascular ischemic stroke (CVI) and malignant diseases 
(lung cancer), without evidence for bleeding disorders.
In 2010, the patient presented with deep venous 
thrombosis (DVT) of the right axillary and brachial 
vein during hormone replacement therapy (HRT). 
Laboratory testing showed prolonged aPTT. Warfa-
rin therapy was initiated achieving therapeutic INR, 
followed by treatment with acetylsalicylic acid 100 mg 
per day aft er two years of warfarin, without hemor-
rhagic complications.
In January 2014, she underwent cholecystectomy due 
to acute cholecystitis and received thromboprophylax-
is with low molecular weight heparin (LMWH) post-
operatively while being in the hospital. Th ree weeks 
aft er discharge from the hospital, she was urgently 
hospitalized to the intensive care unit due to massive 
pulmonary embolism, DVT of the right leg, paroxys-
mal atrial fi brillation and non-sustained ventricular 
tachycardia. Again, very prolonged aPTT (>150 s) was 
noted, without hemorrhagic diathesis. She was treat-
ed with therapeutic doses of LMWH with bridging to 
warfarin.
Aft erwards, in December 2014, the patient was re-
ferred to a hematologist at the Center for Inherited and 
Acquired Disorders of Hemostasis, Zagreb University 
Hospital Center and extended diagnostic workup re-
peatedly revealed a very low activity of FXII (<0.02 KI-
U/L), elevated activity of FVIII (2.52-3.5 KIU/L) and 
VWF (VWF:RCo 251%, VWF:Ag 317%). JAK2V617F 
mutation was found (with low erythropoietin level and 
periodically with very discrete increase in hemoglo-
bin concentration) indicating JAK2-mutation positive 
chronic MPN, most likely PV. She did not have spleno-
megaly on abdominal ultrasound (US) and she refused 
bone marrow analysis that was suggested to confi rm 
and distinguish the subtype of JAK2-mutation posi-
tive chronic MPN. Furthermore, heterozygous poly-
morphism for the MTHFR gene was confi rmed, while 
polymerase chain reaction (PCR) analysis of Factor 
V Leiden and FII 20210A showed no alterations. Ho-
mocysteine levels were normal, while protein S and C 
activities were slightly decreased (protein C 52%, pro-
tein S 38.6%; the patient was on warfarin at the time of 
sampling). Chest x-ray and abdominal US were within 
the normal range. Serum tumor markers were within 
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the normal range and laboratory tests for antiphospho-
lipid syndrome and other most common autoimmune 
disorders were completely negative. Acetylsalicylic 
acid therapy was started along with warfarin aft er con-
formation of positive JAK2V617F mutation.
At 5-month follow-up, a slight increase in the red blood 
cell/hemoglobin/hematocrit, platelet and leukocyte 
count in peripheral blood was noted, still without sple-
nomegaly, and cytoreductive therapy with hydroxy-
urea at a daily dose of 500 mg was initiated because of 
JAK2-mutation positive chronic MPN, most likely PV.
During the next 4-year follow-up, the patient was 
without thromboembolic incidents, adequately an-
ticoagulated with INR within the therapeutic range, 
without hemorrhagic diathesis despite dual antico-
agulation and antiaggregation therapy and with per-
manently prolonged aPTT and very low FXII, with 
normal complete blood count on hydroxyurea therapy 
and without splenomegaly.
Reversible and irreversible risk factors for thrombosis 
in this patient are shown in Figure 1.
Fig. 1. Risk factors for VTE
Th is fi gure shows risk factors for our patient with recurring VTE. She 
had 2 transient risk factors (HRT and operation) while also having 
FXII defi ciency and obesity. Also in 2014 she was diagnosed with MPN
which by itself is higly associated with thromboembolic incidents.
DISCUSSION 
Th e association between FXII defi ciency and throm-
botic disease has always been the subject of interest 
and discussion. Several studies have shown that FXII 
defi ciency may increase the risk of thrombosis. A study 
by Lämmle et al. suggested that homozygous FXII de-
fi ciency may be associated with an increased risk of 
venous thrombosis, while partial FXII defi ciency by 
itself is not a strong risk  factor  for thrombosis (18). 
Another study revealed that half of normal plasma 
concentration of FXII seemed to be suffi  cient for ves-
sel-occlusive clot formation (19). A study that investi-
gated the prevalence of venous thrombosis in patients 
with factor FXII defi ciency showed that at the time of 
thrombosis, other concomitant acquired or congenital 
prothrombotic conditions were present (20).
Venous thromboembolism is a complex disease re-
lated to interactions between both modifi able and 
non-modifi able risk factors. In our patient, there were 
several factors of permanent hypercoagulability of the 
blood, including severe FXII defi ciency, repeatedly el-
evated activity of FVIII and VWF, JAK2-mutation pos-
itive MPN accompanied by acquired prothrombotic 
conditions such as extreme obesity, HRT and surgery 
(Fig. 1). Th e cumulative eff ect of these acquired pro-
thrombotic conditions probably contributed more to 
the development of venous thromboembolism than 
the FXII defi ciency alone.
Due to acquired and hereditary thrombophilia, re-
current thrombotic events and no bleeding problems, 
long-term dual anticoagulation and antiaggregation 
therapy is indicated in our patient.
Coagulation factor XII also has other important roles. 
It has been associated with hereditary angioedema, 
where C1-inhibitor defi ciency causes uncontrolled 
proteolytic activity of FXII with excessive bradykinin 
formation and angioedema (21). Th e activation of the 
kallikrein-kinin system via FXIIa has also been proven 
to be involved in various acute and chronic infl amma-
tory conditions such as sepsis or rheumatoid arthritis 
(22,23). Susceptibility to infections may also be due to 
reduced neutrophil activation in FXII defi cient patients 
(24). FXII defi ciency has also been strongly associated 
with primary and secondary recurrent abortions, due 
to microthrombi of the placenta vessel and placen-
ta infarction, leading to adverse outcomes (25). Our 
patient also had a history of one abortion. Currently, 
studies are focused on the role of coagulation FXII in 
the pathophysiology of cardiovascular and cerebrovas-
cular diseases. Recent studies have shown that FXII 
contributes to atherothrombosis and stroke, while its 
defi ciency provides thromboprotection from mechan-
ical and chemical induced arterial thrombosis in mice 
(26,27). Additional cohorts of FXII defi cient patients 
are needed to study the association with thrombosis.
Th e lack of information regarding this rare condition 
might be due to the limited number of national reg-
istries, which leads to inappropriate diagnosis and 
management, but creation of patient registries could 
help resolve this problem. A retrospective analysis of 
36 patients with FXII defi ciency referred to our Center 
for Inherited and Acquired Disorders of Hemostasis 
during the 2005-2017 period was conducted. Out of 
36 patients, nearly half were men, while the median 
age was 45.5 (range, 17-89) years. In 20 patients, the 
reason for consulting a hematologist was preoperative 
Risk factors 




Operation     
  
HRT     
  
MPN             
  
FXII 
deficiency                     
  
Obesity                     
  
                      
2010 2011 2012 2013 2014 2015 2016 2017 2018 year 
VTE VTE 
E. Ranković, D. Pulanić
A patient with FXII defi ciency, JAK2-mutation positive chronic myeloproliferative neoplasm and recurrent thromboembolic events
Acta Med Croatica, 73 (2019) 209-213
212
workup, while 16 patients were referred due to pro-
longed aPTT. Only nine (25%) patients had very re-
duced FXII levels (<0.02 KIU/L), which was clinically 
manifested with mild bleeding in fi ve patients and re-
current infections in six patients, whereas 13 (36.1%) 
patients had thrombotic events, mainly venous throm-
boembolism (eight patients had VTE and fi ve patients 
presented with arterial thrombosis) (28).
To conclude, a repeatedly prolonged aPTT in a patient 
without hemorrhagic diathesis requires additional 
workup for a possible FXII defi ciency with still several 
open questions regarding its clinical signifi cance and 
treatment modalities. 
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Uvod i cilj: Manjak faktora XII (FXII) je rijedak poremećaj povezan s produženim testom koagulacije (APTV) laboratorijski 
ukazujući na moguću sklonost krvarenju, no bez klinički značajnih krvarenja. Suprotno laboratorijskom nalazu, klinički je 
povezan s povećanim rizikom razvoja tromboembolijskih incidenata. Cilj ovoga rada je prikazati bolesnicu s teškim manj-
kom FXII, izrazito produženim APTV-om, ponavljajućim tromboembolijskim incidentima i dijagnozom JAK2-mutacija pozi-
tivne kronične mijeloproliferativne neoplazme (MPN) bez hemoraške dijateze unatoč dvojnoj antikoagulacijskoj i antiagre-
gacijskoj terapiji. Također je učinjen pregled literature o manjku FXII i njegovom kliničkom značenju, s otvorenim pitanjima 
o ovom rijetkom koagulacijskom poremećaju. Prikaz bolesnice: Prikazujemo bolesnicu rođenu 1959. godine s anamnezom 
izrazite pretilosti i arterijske hipertenzije. Bolesnica je 2010. godine imala duboku vensku trombozu (DVT) desne ruke tije-
kom uzimanja hormonske nadomjesne terapije. Tada se u laboratorijskim nalazima veriﬁ cirao produženi APTV. Primala je 
varfarin tijekom dvije godine nakon čega je uvedena terapija acetilsalicilnom kiselinom, bez hemoraških komplikacija. U 
siječnju 2014. nakon kolecistektomije dolazi do razvoja masivne plućne embolije, DVT desne noge uz ponovno veriﬁ ciran 
vrlo produženi APTV (>150 s), klinički bez znakova hemoraške dijateze. Liječena je niskomolekularnim heparinom s premo-
štavanjem na varfarin. Upućena je hematologu zbog produženog APTV-a, a učinjenom se ekstenzivnom obradom utvrde 
vrlo niska aktivnost FXII (<0,02 KIU/L), povišena aktivnost FVIII (2,52 KIU/L) i VWF (VWF:RCo 251 %, VWF:Ag 317 %) te toč-
kasta mutacija V617F u genu za JAK2, nakon čega je uvedena i acetilsalicilna kiselina uz varfarin, a kasnije i citoreduktivna 
terapija hidroksiurejom zbog JAK2-mutacija pozitivne kronične MPN. Tijekom iduće 4 godine praćenja bolesnica je bez no-
vih tromboembolijskih incidenata, dostatno antikoagulirana, bez hemoraških incidenata unatoč dvojnoj antikoagulacijskoj 
i antiagregacijskoj terapiji i trajno izrazito produženom APTV-u. Zaključak: Ponavljajući produženi APTV u osobe koja nema 
znakove krvarenja zahtijeva obradu na mogući manjak kontaktnih faktora uključujući FXII. U prikazane bolesnice sa steče-
nom i nasljednom tromboﬁ lijom i ponavljajućim trombotskim incidentima indicirana je dugotrajna dvojna antikoagulantna i 
antiagregacijska terapija koju dobro podnosi bez krvarećih komplikacija.
Ključne riječi: manjak FXII, tromboembolijski incidenti, produženo APTV, krvarenje, mijeloproliferativna neoplazma
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